| In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model H Wang, O Milberg, IH Bartelink, P Vicini, B Wang, R Narwal, L Roskos, ... Royal Society Open Science 6 (5), 2019 | 65 | 2019 |
| Conducting a virtual clinical trial in HER2-negative breast cancer using a quantitative systems pharmacology model with an epigenetic modulator and immune checkpoint inhibitors H Wang, RJ Sové, M Jafarnejad, S Rahmeh, EM Jaffee, V Stearns, ... Frontiers in Bioengineering and Biotechnology 8, 141, 2020 | 41 | 2020 |
| Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer H Wang, H Ma, RJ Sové, LA Emens, AS Popel Journal for immunotherapy of cancer 9 (2), 2021 | 38 | 2021 |
| Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model H Ma, H Wang, RJ Sové, J Wang, C Giragossian, AS Popel Journal for immunotherapy of cancer 8 (2), 2020 | 37 | 2020 |
| QSP‐IO: a quantitative systems pharmacology toolbox for mechanistic multiscale modeling for Immuno‐oncology applications RJ Sové, M Jafarnejad, C Zhao, H Wang, H Ma, AS Popel CPT: pharmacometrics & systems pharmacology 9 (9), 484-497, 2020 | 36 | 2020 |
| A quantitative systems pharmacology model of T cell engager applied to solid tumor H Ma, H Wang, RJ Sove, M Jafarnejad, CH Tsai, J Wang, C Giragossian, ... The AAPS Journal 22, 1-16, 2020 | 27 | 2020 |
| Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model A Ruiz-Martinez, C Gong, H Wang, RJ Sové, H Mi, H Kimko, AS Popel PLoS computational biology 18 (7), e1010254, 2022 | 26 | 2022 |
| Systems biology of angiogenesis signaling: Computational models and omics Y Zhang, H Wang, RHM Oliveira, C Zhao, AS Popel WIREs mechanisms of disease 14 (4), e1550, 2022 | 25 | 2022 |
| Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model RJ Sové, BK Verma, H Wang, WJ Ho, M Yarchoan, AS Popel Journal for immunotherapy of cancer 10 (11), 2022 | 24 | 2022 |
| Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response S Zhang, C Gong, A Ruiz-Martinez, H Wang, E Davis-Marcisak, ... Immunoinformatics 1, 100002, 2021 | 24 | 2021 |
| Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer H Wang, C Zhao, CA Santa-Maria, LA Emens, AS Popel IScience 25 (8), 2022 | 23 | 2022 |
| Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition H Wang, T Arulraj, H Kimko, AS Popel NPJ Precision Oncology 7 (1), 55, 2023 | 10 | 2023 |
| A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition T Arulraj, H Wang, LA Emens, CA Santa-Maria, AS Popel Science Advances 9 (26), eadg0289, 2023 | 9 | 2023 |
| Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial S Zhang, A Deshpande, BK Verma, H Wang, H Mi, L Yuan, WJ Ho, ... bioRxiv, 2023 | 6 | 2023 |
| Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager S Anbari, H Wang, Y Zhang, J Wang, M Pilvankar, M Nickaeen, S Hansel, ... Frontiers in Pharmacology 14, 1163432, 2023 | 6 | 2023 |
| Eliciting the antitumor immune response with a conditionally activated PD‐L1 targeting antibody analyzed with a quantitative systems pharmacology model A Ippolito, H Wang, Y Zhang, V Vakil, H Bazzazi, AS Popel CPT: Pharmacometrics & Systems Pharmacology 13 (1), 93-105, 2024 | 4 | 2024 |
| Integration of Clinical Trial Spatial Multi-omics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery S Zhang, A Deshpande, BK Verma, H Wang, H Mi, L Yuan, WJ Ho, ... Cancer Research, 2024 | | 2024 |
| Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC A Ippolito, H Wang, Y Zhang, V Vakil, AS Popel Journal of Pharmacokinetics and Pharmacodynamics, 1-11, 2024 | | 2024 |
| Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC H Wang, T Arulraj, S Anbari, AS Popel Clinical and Translational Science 17 (6), e13811, 2024 | | 2024 |
| Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology T Arulraj, H Wang, A Ippolito, S Zhang, EJ Fertig, AS Popel Briefings in bioinformatics 25 (3), bbae131, 2024 | | 2024 |
Aleksander S. PopelProfessor of Biomedical Engineering, Johns Hopkins University, School of Medicine在 jhu.edu 的电子邮件经过验证
